66 results about "Intimal proliferation" patented technology

The invention provides methods for treating injuries to one or more internal structures of a subject by administering a drug delivery vehicle to an external surface of the injured structure. The drug delivery vehicle substantially adheres to the site of administration and provides for the release of a bioactive agent that reduces or prevents further injury to the internal structure by disease processes, such as hyperplasia.

A broad class of photosensitive compounds having enhanced in vivo target tissue selectivity and versatility in photodynamic therapy. Many furocoumarin compounds, such as psoralens, exhibit cytostatic activity when photoactivated but exhibit little in vivo specificity for selectively accumulating in any particular target tissue such as atheromatous plaques. Reactive Oxygen Producing Photosensitizers ("ROPPs") are photoactivatable compounds having an affinity for hyperproliferating cells (such as atheromatous plaque cells), which when photoactivated, produce cytotoxic reaction products. The photoactivity of a ROPP, such as a porphyrin, may be reduced by metalating the porphyrin while the selective affinity of the metalized ROPP for hyperproliferating tissue remains substantially unchanged. By linking a furocoumarin compound to a ROPP to form a F-ROPP, the cytostatic properties of the furocoumarin portion of the F-ROPP can be exploited while the selective affinity of the ROPP portion of the compound for hyperproliferating cells such as atheromatous plaque provides enhanced tissue selectivity without cytotoxicity. In vivo, certain F-ROPPs may be forced to selectively accumulate in a target tissue by illuminating only the target tissue with light having a wavelength operable for photoactivating the F portion of the F-ROPP thereby causing the F-ROPP to either form a monoadduct with or crosslink the cellular DNA in the target tissue. Light of a second wavelength can then be delivered to the target tissue to photoactivate the ROPP portion causing further interference with cellular activity.

The invention relates a medicine-carrying cutting balloon dilating catheter. The medicine-carrying cutting balloon dilating catheter comprises a cutting balloon dilating catheter body and a medicine coating, wherein the cutting balloon dilating catheter body comprises a balloon, the surface of the balloon is provided with a plurality of blades, and the medicine coating is coated on the surfaces of the balloon and the blades. The medicine-carrying cutting balloon dilating catheter can cut plaques in vessels and fully dilate to be well adhered to arterial walls by pressing the plaques, so that not only subsequent inflammatory responses are reduced, but also the dilation of lumen reduces the restenosis rate. Besides, the medicine coating can restrain the intimal hyperplasia of the vessel inner surface which is damaged by squeezing. Particularly for a bended complex lesion location where a stent cannot reach, the superior advantages of the medicine-carrying cutting balloon dilating catheter are significant.

Vascular smooth muscle cells (VSMCs) adhere to and orient along micropatterned grooves having a depth of 1 to 10 μm and a width of 1 to 20 μm that are imposed on the surface of a vascular implant device. The VSMCs maintain an elongated morphology and reduced proliferation resulting in a decrease in occurrence of intimal hyperplasia upon device implantation.

Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g. using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered.

Various compositions and methods of producing a medical device are provided herein. Such medical devices include, for example, stents, stent-grafts, synthetic artificial blood vessels, heart valves, etc., all coated with biocompatible matrices containing various antibodies, antibody fragments, or small molecule substances Clothes. The biocompatible matrix has the ability to recognize, bind and/or interact with surface antigens of progenitor cells, thereby immobilizing said cells on the surface of the device. The coating material used for this device may also contain a compound or growth factor that can promote the process of adhesion, growth and differentiation of the progenitor endothelial cells on the surface of the device from a bound cell state to a mature one. and the ability of functional endothelial cells to prevent intimal proliferation. Methods are disclosed herein relating to such medical devices, their various components, and their use in patients with various vascular diseases, e.g., vascular valve restenosis, atherosclerosis, or other types of vascular disorders. Various methods of treatment for problem mammals.

Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin E and/or conjugated linoleic acid. Another aspect of the invention provides a drug eluting device, such as a drug eluting stent, with at least one coating layer comprising a progesterone composition that can minimize or eliminate inflammation, thrombosis, restenosis, neo-intimal hyperplasia, rupturing of vulnerable plaque, and/or other effects related to device implantation, treatment, or interaction. Other aspects of the invention provide for methods of using such compositions, formulations, and devices.

The invention provides a novel retrievable vena cava thrombus multi-filtering device. The multi-filtering device is composed of a retrieve hook, a connecting internal nut, a forked type filter screen, blood vessel fixing stabs, a sine wave filter screen, a tail end and a tail end connecting nut. The structure of the multi-filtering device is formed through integrated cutting processing and welding by adopting laser. The product is in a double-saucer-shaped structure, so that the contact area of the product and the vascular wall is obviously reduced, the intimal hyperplasia area of the vascular wall is greatly reduced, and when the multi-filtering device is retrieved, the damage to the vascular venous wall is obviously reduced, thus the retrievable time of the product in the human body is obviously prolonged. The double-saucer structure of the product is provided with four filtering screens, so that the thrombus filtering times can be increased, the thrombus filtering efficiency can be improved, while the thrombus is filtered, the passing of the blood is not blocked, therefore, the relapse risk of pulmonary embolism and the risk of the vein occlusion after the patient is treated by adopting the thrombus filtering device is greatly reduced.

The invention belongs to the technical field of medical apparatus and instruments, and specially relates to the technical field capable of performing damage endothelium repair on a device implantationposition. The invention provides an application of anti-adhesion polypeptide in preparation of an implanted medical instrument. The implanted medical device is loaded with a cell trapping substance and the anti-adhesion polypeptide. A preparation method of the implanted medical instrument includes the following steps: loading the cell trapping substance on a surface of the cell trapping substancethat the implanted medical device plan to load, and loading the anti-adhesion polypeptide into a hole or a groove of the implanted medical device. According to the technical scheme, from the perspective of anti-cell adhesion, a mechanism of combining the anti-adhesion peptide with an adhesion molecule on a cell membrane is adopted, and the adhesion of other types of cells except captured specialcells to the surface of the implanted medical device is blocked, and therefore, the purity of the captured cells can be greatly improved, the efficiency of endothelial repair is improved, thereby achieving the purpose of promoting endothelial neogenesis, inhibiting intimal hyperplasia, and inhibiting an inflammatory reaction.

An intimal hyperplasia inhibitor containing a 3(2H)-pyridazinone compound represented by the formula (I):

[wherein each of R¹, R² and R³ is independently a hydrogen atom or a C_1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C_1-8 alkylene which may be substituted with a hydroxyl group] or a pharmacologically acceptable salt thereof.

The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signaling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.

The invention relates to an alternately released double slow release coating multi-functional small-bore artificial blood vessel which comprises an artificial blood vessel, wherein double-layered coatings are sprayed to the inner and outer surfaces of the artificial blood vessel, the inner coating of the double-layered coating is a PTX slow release PDMS coating PTX-PDMS and the outer coating thereof is a biodegraded VEGF gene encapsulated polylactic-hydroxyacetic acid copolymer nano microparticle slow release coating PLGA-NPs. Purposes that VEGF gene transfection expression promotes rapid endothelialization of the inner wall of the blood vessel in an early implanting stage and PTX is continuously released to inhibit follow-up intimal hyperplasia in the later stage are achieved by means of a small-bore PET blood vessel formed by the inner PTX-PDMS coating and the outer VEGF gene encapsulated PLGA-NPs slow release coating, and the multi-functional artificial blood vessel plays a synergistic role between promoting migration, proliferation and maturity of endothelial cells and inhibiting vascular smooth muscle cells of a transmembrane, so that good endothelialization of inner wall of the blood vessel and long-term smoothness after implanting are guaranteed, and the long-term smoothness of the small-bore artificial blood vessel can be obviously improved.

The invention discloses a polyethylene glycol and polypeptide co-modified small-diameter artificial blood vessel and a preparation method thereof. The preparation method includes the steps of firstly,dissolving PCL-PIBMD and silk fibroin into hexafluoroisopropanol to obtain a spinning solution; secondly, subjecting the spinning solution to electrospinning to obtain a vessel 50-200 micrometers inthickness, 1-5mm in inner diameter and 2cm in length; thirdly, soaking the vessel into a first solution to obtain a surface aminated vessel, wherein the first solution is prepared by adding dopamine and hexanediamine into a Tris-HCl buffer solution; fourthly, adding bifunctional polyethylene glycol and cell adhesion peptides into a second solution to obtain a third solution, and soaking the surface aminated vessel into the third solution to obtain the polyethylene glycol and polypeptide co-modified small-diameter artificial blood vessel. The preparation method has the advantages that the method is simple and practicable to operate; the prepared small-diameter artificial blood vessel is good in biocompatibility and biodegradability, capable of inhibiting the adhesion of blood components tothe surface of the artificial blood vessel, capable of preventing thrombosis and intimal hyperplasia and less prone to restenosis and restenosis.

The invention discloses a multi-structure artificial blood vessel scaffold with an inner layer capable of releasing NO gas and a preparation method thereof. The artificial blood vessel scaffold comprises the inner layer, a middle layer and an outer layer. The middle layer is sleeved with the outer layer. The inner layer is sleeved with the middle layer. The inner layer is made from electrostatic spinning fiber. The electrostatic spinning fiber is formed by mixing hydrosol and substances capable of releasing NO gas. The substances capable of releasing the NO gas are uniformly dispersed in an electrostatic spinning solution of the hydrosol in a wrapping mode, then, the micro-sol electrostatic spinning technology is adopted for constructing the nanofiber small-diameter vessel scaffold, so that a micro-sol electrostatic spinning fiber membrane with the inner layer with the substances capable of releasing NO gas is prepared, and then the multi-structure artificial blood vessel scaffold with the inner layer capable of releasing NO gas is obtained. The method is simple in preparation, convenient to implement, high in drug loading efficiency, and can slowly release NO gas. The thrombus resistance and the effect of restraining intimal hyperplasia are achieved by releasing NO gas.

To prevent intimal hyperplasia within a dialysis graft, a flexible tube comprising the dialysis graft is coated interiorly before placement with an anticarcinogen or mitosis-inhibiting agent for preventing cell division. The graft can also be irradiated with light energy by directing light into the lumen of the tube that has been grafted in place, thereby preventing or reducing dialysis graft intimal hyperplasia and reducing inflammation. The light source can be a light emitting diode (LED) or a chemical light source, i.e., a chemiluminescent substance for producing cool light energy within the graft to prevent or reduce the symptoms of GIH. When phototherapy is used, the body is exposed to light radiation at the site of the graft in sufficient amount to prevent undesired cell proliferation within the vessels, the graft, or surrounding tissue where the invention is used without detectable damage to body tissue. For various applications, visible light can be used, e.g., visible blue or red light or the combination is employed. Blue and red light can be produced by an incandescent lamp or other suitable lamp, an LED, a laser or chemical light source with wavelengths predominantly between about 300 nm to about 800 nm.

The invention discloses new application of KFL4, a kruppel-like transcription factor. The application refers to the application of coding gene of the kruppel-like transcription factor 4 protein in preparing medicines for treating intimal hyperplasia. The invention discloses a medicine with the kruppel-like transcription factor 4 protein or coding gene thereof as target spots for treating intimal hyperplasia, the active ingredients thereof are micro RNA or si RNA or recombinant vector of coding gene containing the kruppel-like transcription factor 4 protein, which overexpress the kruppel-like transcription factor 4. Experiments indicate that the application method or the medicine of the invention can effectively inhibit proliferation of vascular smooth muscle cell, so as to inhibit hyperplasia of endangium, the inhibiting effect is very obvious; therefore, the method and medicine of the invention enjoy very broad application prospect in treating hyperplasia of endangium.

The invention discloses an application of alisol A in preparation of anti-atherosclerosis medicaments. Animal tests prove that the alisol A has a significant treatment effect on an arteriosclerosis model of an ApoE-/- mouse which is fed with a high-fat diet and combined with carotid artery injury surgery. The medicament disclosed by the invention has relatively low toxicity and is suitable for long-term use. The invention provides the medicament for treating arteriosclerosis, which has the advantages of exact curative effect, definite ingredients and controllable quality, and can meet the needs of clinical applications, by applying the modern medicine theory. The effect of inhibiting vascular intimal hyperplasia of the ApoE-/- mice after carotid artery injuries, caused by high-fat diets, of the alisol A is firstly disclosed by the invention, thereby showing that the alisol A has an obvious effect on treating the arteriosclerosis.

The invention belongs to the technical field of polymer materials, and in particular relates to a degradable shape-memory intraluminal stent and a preparation method thereof. The present invention uses lactide, glycolide or ε-caprolactone, biodegradable polyester and diisocyanic acid as raw materials, and prepares the thermally induced deformation temperature transition point (Ttrans) of about 42°C through bulk melt polymerization. Degradable polymer materials, the obtained materials are processed and shaped above the melting temperature (Tm) to make helical tubular stents for different lumens; under the condition of T>Ttrans, stress is applied, and processed into stents for easy operation Shape; freeze-set stress relief, off-the-shelf product. The shape-memory intraluminal stent prepared by the method of the present invention has good biocompatibility, provides temporary support for the narrow lumen, has no long-term complications and does not need to be taken out after operation, and finally completely degrades in vivo After metabolism, it can be used as a carrier to carry anti-thrombotic and anti-intimal hyperplasia drugs, without the need for long-term systemic anticoagulation and other advantages.

The invention provides a natto healthcare product with lipid lowering and blood pressure reducing effects. The healthcare product is prepared from natto, orange peel, hawthorn, liquorice, green tea and milk powder; the healthcare product is prepared by the processes of decocting the orange peel, the hawthorn and the green tea into a liquid, carrying out spray drying to form powder, mixing the powder with the natto and the milk powder and carrying out freeze drying and crushing. According to the healthcare product, the harmful substance to a human body can be reduced, toxin elimination is accelerated, the liver detoxification burden is relieved, the physical strength is effectively enhanced, the liver is protected, fatigue discomfort is removed and the natto healthcare product has the healthcare function of regulating the physiological function. The product has relatively high fibrin dissolving activity and has a relatively good effect on intimal hyperplasia, blood circulation and cardiovascular health can be improved and the onset risk of thrombus is reduced.